These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11122738)

  • 21. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 22. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering therapies in the management of acute coronary syndromes.
    Mosca L; Biviano A;
    Curr Cardiol Rep; 2002 Jul; 4(4):320-6. PubMed ID: 12052271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the benefits of lipid-lowering therapy.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):2M-4M. PubMed ID: 9766341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future of lipid-lowering trials: what else do we need to know?
    Jones PH
    Am J Cardiol; 1998 Sep; 82(6A):32M-38M. PubMed ID: 9766346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering therapy for elderly patients at risk for coronary events and stroke.
    Courville KA; Lavie CJ; Milani RV
    Am Heart Hosp J; 2005; 3(4):256-62. PubMed ID: 16330918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing the efficacy of lipid-lowering therapy versus revascularization: the time has come, or is it past due?
    Enas EA
    Circulation; 1998 Jun; 97(25):2584-6. PubMed ID: 9657483
    [No Abstract]   [Full Text] [Related]  

  • 32. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm.
    Nastasi DR; Norman R; Moxon JV; Quigley F; Velu R; Jenkins J; Golledge J
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):643-650. PubMed ID: 34507892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-lowering drug therapy in elderly patients.
    Berthold HK; Gouni-Berthold I
    Curr Pharm Des; 2011; 17(9):877-93. PubMed ID: 21418034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study in primary care in patients without vascular disease comparing levels of coronary risk factors in those recommended for lipid-lowering drugs based on either absolute risk or absolute risk reduction.
    Ramachandran S; Croft P; Neary RH
    Prev Cardiol; 2003; 6(1):17-21. PubMed ID: 12624557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lipid lowering therapy on progression of coronary and carotid artery disease.
    Ballantyne CM; Herd JA; Dunn JK; Jones PH; Farmer JA; Gotto AM
    Curr Opin Lipidol; 1997 Dec; 8(6):354-61. PubMed ID: 9412776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG
    Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The health economics of the treatment of hyperlipidemia and hypertension.
    McMurray J
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):99S-104S. PubMed ID: 10555609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy].
    Steinmetz A; Noll B; Maisch B; Schäfer JR
    Z Kardiol; 1998; 87 Suppl 2():205-9. PubMed ID: 9827484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.